Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).
Myelodysplastic Syndrome
DRUG: CC-1088
The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).